secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOLIFE SOLUTIONS INC (BLFS)
CIK:        0000834365
Form:       8-K
Filed at:   2026-07-22T21:17:19+00:00
Accession:  0001628280-26-049232
Event type: m_and_a
Sentiment:  positive
Materiality: 1.00
Item codes: 1.01, 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Repligen to acquire BioLife for $1.5B enterprise value, $31.00 per share
------------------------------------------------------------------------

- Repligen to acquire BioLife for $31.00/share (0.1442 RGEN shares + $11.25 cash); total enterprise value ~$1.5B.
- Transaction expected to close in Q4 2026, subject to BioLife stockholder approval and regulatory clearances.
- BioLife reports preliminary Q2 revenue growth ~21% YoY; Repligen reports preliminary Q2 revenue growth ~12-13% organic.
- Deal expected to be accretive to Repligen's adjusted EPS by at least $0.05 in year one and at least $0.25 in year two.
- Termination fee of $59M payable by BioLife under certain circumstances if deal fails.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/834365/000162828026049232/0001628280-26-049232-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/834365/000162828026049232/blfs-20260721.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-049232

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer